The COVID-19 vaccine will leverage new distribution approaches, so monitoring its physical integrity through the supply chain from manufacturing to point of use will also require fresh thinking. With a lot at stake for all parties involved such as regulators, pharmaceutical companies, and the general population, Vidya Subramanian at Roambee explains why the margins for error in delivering a vaccine promptly and with uncompromised efficacy have never been tighter.